Novavax expanded its collaboration and license agreement with SK Bioscience for manufacture and commercialization of NVX-CoV2373 in South Korea, including a 40 million dose advance purchase agreement with the Korean government. Estimated ~$300M cumulative deal value across upfront, milestones and supply.